DR. STEVEN JAMES FREEDMAN, M.D./PH.D.
Osteopathic Medicine in Philadelphia, PA
License number
Pennsylvania MD422363
Category
Osteopathic Medicine
Type
Hematology & Oncology
License number
Pennsylvania 158662
Category
Osteopathic Medicine
Type
Hematology & Oncology
Address
Address
2
39TH & Market Streets - SUITE 105, Philadelphia, PA 19104
1250 Fairland Dr, Prospectville, PA 19002
1250 Fairland Dr, Prospectville, PA 19002
Phone
(215) 662-9960
Personal information
See more information about STEVEN JAMES FREEDMAN at radaris.comName
Address
Phone
680 Foxcroft Rd, Elkins Park, PA 19027
1460 Willow Dr, Easton, PA 18040
1438 Wynnemoor Way, Fort Washington, PA 19034
1250 Fairland Dr, Ambler, PA 19002
348 Windsor Ave, Southampton, PA 18966
Professional information
See more information about STEVEN JAMES FREEDMAN at trustoria.com
Dr. Steven J Freedman, Ambler PA - MD (Doctor of Medicine)
Dr. Steven J Freedman, Ambler PA - MD (Doctor of Medicine)
Specialties:
Hematology, Medical Oncology, Oncology
Address:
1250 Fairland Dr, Ambler 19002
Certifications:
Hematology, 2004, Internal Medicine, 2000, Medical Oncology, 2003
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
Tufts University
Graduated: 1993
University Of California-San Francisco
Beth Israel Deaconess Med Ctr-Harvard U
Dana-Farber Cancer Inst
Tufts University
Graduated: 1993
University Of California-San Francisco
Beth Israel Deaconess Med Ctr-Harvard U
Dana-Farber Cancer Inst
Ret Tyrosine Kinase Inhibition
Ret Tyrosine Kinase Inhibition
US Patent:
2009022, Sep 10, 2009
Filed:
Jan 22, 2007
Appl. No.:
12/223042
Inventors:
Carolyn A. Buser-Doepner - Harleysville PA, US
Steven J. Freedman - Ambler PA, US
Cheryl A. Pickett - Blue Bell PA, US
Steven J. Freedman - Ambler PA, US
Cheryl A. Pickett - Blue Bell PA, US
International Classification:
A61K 31/506, A61P 35/00, C12N 9/99
US Classification:
51425219, 435184
Abstract:
The present invention provides methods for inhibiting RET tyrosine kinase. Further, the present invention also provides methods of treating or preventing thyroid cancer.
Jak2 Tyrosine Kinase Inhibition
Jak2 Tyrosine Kinase Inhibition
US Patent:
2009006, Mar 5, 2009
Filed:
Jan 22, 2007
Appl. No.:
12/223043
Inventors:
Carolyn A. Buser-Doepner - Harleysville PA, US
Steven J. Freedman - Ambler PA, US
Jackson B. Gibbs - Chalfont PA, US
Frank J. Giles - Bellaire TX, US
Christopher G. Marshall - Framingham MA, US
John R. Pollard - Oxfordshire, GB
Steven J. Freedman - Ambler PA, US
Jackson B. Gibbs - Chalfont PA, US
Frank J. Giles - Bellaire TX, US
Christopher G. Marshall - Framingham MA, US
John R. Pollard - Oxfordshire, GB
International Classification:
A61K 31/506, A61P 35/02
US Classification:
51425219
Abstract:
The present invention provides methods for inhibiting JAK2 tyrosine kinase. Further, the present invention also provides methods of treating or preventing myeloproliferative disorders.
Jak2 Tyrosine Kinase Inhibition
Jak2 Tyrosine Kinase Inhibition
US Patent:
2010032, Dec 23, 2010
Filed:
Aug 5, 2010
Appl. No.:
12/850920
Inventors:
Carolyn A. Buser-Doepner - Harleysville PA, US
Steven J. Freedman - Ambler PA, US
Jackson B. Gibbs - Chalfont PA, US
Frank J. Giles - Bellaire TX, US
Christopher G. Marshall - Framingham MA, US
John R. Pollard - Abingdon, GB
Steven J. Freedman - Ambler PA, US
Jackson B. Gibbs - Chalfont PA, US
Frank J. Giles - Bellaire TX, US
Christopher G. Marshall - Framingham MA, US
John R. Pollard - Abingdon, GB
International Classification:
A61K 31/496, A61P 35/02, A61P 7/00, C12N 9/99
US Classification:
51425219, 435184
Abstract:
The present invention provides methods for inhibiting JAK2 tyrosine kinase. Further, the present invention also provides methods of treating or preventing myeloproliferative disorders.